FDA Shifts Away from Animal Testing, Charles River (CRL) Shares Could Be Impacted | CRL Stock News

Author's Avatar
Apr 10, 2025
Article's Main Image

The U.S. Food and Drug Administration (FDA) has announced a transformative shift in its drug development protocols, moving away from traditional animal testing. This significant change will impact the creation of monoclonal antibody therapies and various other pharmaceuticals. The FDA plans to adopt methods that are more closely aligned with human biology, which are expected to enhance the safety of new drugs.

By implementing these new strategies, the FDA aims to streamline the drug approval process. This shift is anticipated to lower the necessity for animal testing, thereby reducing research costs and, eventually, the cost of drugs for consumers. The agency believes that these "human-relevant" methods will expedite evaluations and improve overall drug safety.

In response to this development, investors are closely monitoring the stock performance of Charles River Laboratories (CRL, Financial). As a company that supplies nonhuman primates for testing, Charles River may experience significant market reactions due to these regulatory changes. The shift in FDA policy emphasizes a growing trend towards more ethical and efficient drug development practices.

Wall Street Analysts Forecast

1910427398940291072.png

Based on the one-year price targets offered by 15 analysts, the average target price for Charles River Laboratories International Inc (CRL, Financial) is $174.33 with a high estimate of $215.00 and a low estimate of $130.00. The average target implies an upside of 80.89% from the current price of $96.38. More detailed estimate data can be found on the Charles River Laboratories International Inc (CRL) Forecast page.

Based on the consensus recommendation from 20 brokerage firms, Charles River Laboratories International Inc's (CRL, Financial) average brokerage recommendation is currently 3.0, indicating "Hold" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.

Based on GuruFocus estimates, the estimated GF Value for Charles River Laboratories International Inc (CRL, Financial) in one year is $204.97, suggesting a upside of 112.68% from the current price of $96.375. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Charles River Laboratories International Inc (CRL) Summary page.

Disclosures

I/We may personally own shares in some of the companies mentioned above. However, those positions are not material to either the company or to my/our portfolios.